SCHEMBL2685255

SCHEMBL2685255

N#Cc1cc(-c2ccoc2)c2ccc(OCc3cccc(C4(O)CC5COC(C4)O5)n3)cc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30108090 1.00 ALOX5 (1.00) ALOX5
SCHEMBL13920494 0.93 ALOX5 (0.87) ALOX5
SCHEMBL9387451 0.88 ALOX5 (0.79) ALOX5
SCHEMBL13696695 0.88 ALOX5 (0.78) ALOX5
SCHEMBL14195268 0.88 ALOX5 (0.78) ALOX5
SCHEMBL9300407 0.86 ALOX5 (1.00) ALOX5
SCHEMBL29519211 0.86 ALOX5 (1.00) ALOX5
SCHEMBL2685256 0.79 ALOX5 (0.66) ALOX5
SCHEMBL8353043 0.78 ALOX5 (0.64) ALOX5
SCHEMBL9303010 0.78 ALOX5 (0.80) ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669289-B2 Methods and compositions relating to hematologic malignancies THE JACKSON LABORATORY (US) 2014-03-11 US disclosed
US-20120114605-A1 METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES THE JACKSON LABORATORY 2012-05-10 US disclosed
WO-2010124283-A2 METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES THE JACKSON LABORATORY (US) 2010-10-28 WO disclosed
US-7790723-B2 Thiazole derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2010-09-07 US disclosed
US-7790723-B2 Thiazole derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2010-09-07 US disclosed
US-7563790-B2 Pyridazine derivatives MERCK PATENT GMBH (DE) 2009-07-21 US disclosed
US-7563790-B2 Pyridazine derivatives MERCK PATENT GMBH (DE) 2009-07-21 US disclosed
US-7544684-B2 Hydrazono-malonitriles MERCK PATENT GMBH (DE) 2009-06-09 US disclosed
US-7544684-B2 Hydrazono-malonitriles MERCK PATENT GMBH (DE) 2009-06-09 US disclosed
US-7470687-B2 Aryl oximes MERCK PATENT GMBH (DE) 2008-12-30 US disclosed
US-7354941-B2 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes PFIZER PRODUCTS INC. (US) 2008-04-08 US disclosed
US-7354941-B2 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes PFIZER PRODUCTS INC. (US) 2008-04-08 US disclosed
US-7312328-B2 Benzoylpyridazines MERCK PATENT GMBH (DE) 2007-12-25 US disclosed
US-7312328-B2 Benzoylpyridazines MERCK PATENT GMBH (DE) 2007-12-25 US disclosed
US-7250518-B2 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-07-31 US disclosed
US-7250518-B2 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-07-31 US disclosed
US-20070161681-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER INC. (US) 2007-07-12 US disclosed
US-20070161681-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER INC. (US) 2007-07-12 US disclosed
US-7183293-B2 Ether derivatives useful as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-02-27 US disclosed
US-7183293-B2 Ether derivatives useful as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161681-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PDE4A, PDE4B, PDE4D ALOX5 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.